Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Share-based Compensation: 2021-2025

Historic Share-based Compensation for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to $289.0 million.

  • Roivant Sciences' Share-based Compensation rose 14.17% to $81.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.2 million, marking a year-over-year increase of 36.14%. This contributed to the annual value of $289.0 million for FY2025, which is 44.78% up from last year.
  • Latest data reveals that Roivant Sciences reported Share-based Compensation of $289.0 million as of FY2025, which was up 44.78% from $199.6 million recorded in FY2024.
  • Roivant Sciences' 5-year Share-based Compensation high stood at $565.0 million for FY2022, and its period low was $85.0 million during FY2021.
  • Over the past 3 years, Roivant Sciences' median Share-based Compensation value was $217.8 million (recorded in 2023), while the average stood at $235.5 million.
  • In the last 5 years, Roivant Sciences' Share-based Compensation soared by 564.98% in 2022 and then tumbled by 61.45% in 2023.
  • Over the past 5 years, Roivant Sciences' Share-based Compensation (Yearly) stood at $85.0 million in 2021, then surged by 564.98% to $565.0 million in 2022, then plummeted by 61.45% to $217.8 million in 2023, then decreased by 8.34% to $199.6 million in 2024, then spiked by 44.78% to $289.0 million in 2025.